17 - STOCK-BASED COMPENSATION

2015 Equity Incentive Plan

On June 26, 2015, the Company’s Board of Directors approved the 2015 Equity Incentive Plan for awards with respect to an aggregate of 400,000 shares of common stock (the “2015 Plan”). Under the 2015 Plan, the Company’s Board of Directors, the Compensation Committee, or another designated committee of the Board of Directors may grant a variety of stock-based incentive awards to the Company’s officers, directors, employees, and consultants. Awards may consist of stock options, stock appreciation rights, dividend equivalent rights, restricted (nonvested) stock, restricted stock units, and unrestricted stock.

On March 23, 2017, the Board of Directors approved an amendment and restatement of the 2015 Plan.  This amendment and restatement increased the number of shares available for awards under the plan from 400,000 to 2,750,000, subject to shareholder approval; set the annual limit for awards to non-employee directors and other

individuals as 500,000 and 1,000,000 shares, respectively; and modified the change in control definition.  The Company’s shareholders approved the increase in the number of shares at the Company’s 2017 Annual Meeting of Shareholders on May 17, 2017.

On March 19, 2021, the Board of Directors approved an amendment and restatement of the 2015 Equity Incentive Plan (the “Amended 2015 Plan”). This amendment and restatement increased the number of shares available for awards under the plan from 2,750,000 to 4,750,000, subject to shareholder approval. The Company’s shareholders approved the increase in the number of shares at the Company’s 2021 Annual Meeting of Shareholders on May 13, 2021.

As of December 31, 2025, the Company has awarded restricted stock units, performance-based restricted stock units, restricted stock and stock options under the Amended 2015 Plan.

Stock Options

 

The Company has issued options to purchase the Company’s shares of common stock to certain individuals. For the years ended December 31, 2025, 2024 and 2023, the Company recognized amortization expense of the fair value of its stock options, which is included in General and administrative expenses, as follows:

For the Years Ended December 31,

 

2025

2024

2023

General and administrative expenses

$

$

6

$

83

There was no remaining unamortized stock-based compensation as of December 31, 2025.

The following table summarizes the stock option activity for the years ended December 31, 2025, 2024 and 2023:

For the Year Ended December 31,

2025

2024

2023

Weighted

Weighted

Weighted

Weighted

Weighted

Weighted

Number

Average

Average

Number

Average

Average

Number

Average

Average

of

Exercise

Fair

of

Exercise

Fair

of

Exercise

Fair

  ​ ​ ​

Options

  ​ ​ ​

Price

  ​ ​ ​

Value

  ​ ​ ​

Options

  ​ ​ ​

Price

  ​ ​ ​

Value

  ​ ​ ​

Options

  ​ ​ ​

Price

  ​ ​ ​

Value

Outstanding as of January 1,

 

302,945

7.91

2.76

368,190

7.93

2.82

415,227

 

$

7.91

$

2.78

Granted

 

Exercised

 

(231,483)

7.30

2.27

(65,245)

8.03

3.09

(47,037)

7.70

2.53

Forfeited

 

Outstanding as of December 31,

 

71,462

 

$

9.91

$

4.33

302,945

 

$

7.91

$

2.76

368,190

$

7.93

$

2.82

Exercisable as of December 31,

 

71,462

 

$

9.91

$

4.33

302,945

 

$

7.91

$

2.76

337,654

$

7.76

$

2.68

The following table summarizes certain information about the options outstanding as of December 31, 2025:

Options Outstanding and Unvested,

Options Outstanding and Exercisable,

December 31, 2025

December 31, 2025

Weighted

Weighted

 

Weighted

Average

 

Weighted

Average

Weighted

Average

Exercise Price of

 

Average

Remaining

Average

Remaining

Outstanding

Number of

Exercise

Contractual

Number of

Exercise

Contractual

Options

  ​ ​ ​

Options

  ​ ​ ​

Price

  ​ ​ ​

Life

  ​ ​ ​

Options

  ​ ​ ​

Price

  ​ ​ ​

Life

 

$

9.91

$

71,462

$

9.91

1.15

As of December 31, 2025 and 2024, a total of 71,462 and 302,945 stock options were outstanding, respectively.

Restricted Stock Units

The Company has granted restricted stock units (“RSUs”) to certain members of the Board of Directors and certain executives and employees of the Company, which represent the right to receive a share of common stock, or in the sole discretion of the Company’s Compensation Committee, the value of a share of common stock on the date that the RSU vests. As of December 31, 2025 and 2024, 1,330,383 and 980,966 shares of the Company’s common stock were outstanding in respect of the RSUs, respectively. Such shares will only be issued in respect of vested RSUs issued to directors when the director’s service with the Company as a director terminates. Such shares of common stock will only be issued to executives and employees when their RSUs vest under the terms of their grant agreements and the Amended 2015 Plan described above.

The RSUs that have been issued to certain members of the Board of Directors generally vest on the date of the annual shareholders meeting of the Company following the date of the grant. In lieu of cash dividends issued for vested and nonvested shares held by certain members of the Board of Directors, the Company will grant additional vested and nonvested RSUs, respectively, which are calculated by dividing the amount of the dividend by the closing price per share of the Company’s common stock on the dividend payment date and will have the same terms as other RSUs issued to members of the Board of Directors. The RSUs that have been issued to other individuals vest in equal installments on each of the anniversaries of the determined vesting date, over the three or five year vesting periods, as applicable.

The table below summarizes the Company’s unvested RSUs for the years ended December 31, 2025, 2024 and 2023:

For the Years Ended December 31,

2025

2024

2023

Weighted

Weighted

Weighted

Number of

Average Grant

Number of

Average Grant

Number of

Average Grant

  ​ ​ ​

RSUs

Date Price

RSUs

Date Price

RSUs

  ​ ​ ​

Date Price

 

Outstanding as of January 1,

554,686

$

17.65

563,705

$

16.47

641,972

$

15.74

Granted

349,464

14.73

235,109

18.84

214,497

16.26

Vested

(267,300)

17.80

(244,128)

16.07

(243,442)

14.36

Forfeited

(1,966)

16.96

(49,322)

16.42

Outstanding as of December 31,

634,884

$

15.98

554,686

$

17.65

563,705

$

16.47

The total fair value of the RSUs that vested during the years ended December 31, 2025, 2024 and 2023 was $3,830, $4,930 and $4,260, respectively. The total fair value is calculated as the number of shares vested during the period multiplied by the fair value on the vesting date.

The following table summarizes certain information of the RSUs unvested and vested as of December 31, 2025:

Unvested RSUs

Vested RSUs

December 31, 2025

December 31, 2025

Weighted

Weighted

Average

Weighted

Average

Remaining

Average

Number of

Grant Date

Contractual

Number of

Grant Date

RSUs

  ​ ​ ​

Price

  ​ ​ ​

Life

  ​ ​ ​

RSUs

  ​ ​ ​

Price

 

634,884

$

15.98

0.88

280,702

$

13.87

The Company is amortizing these grants over the applicable vesting periods, net of anticipated forfeitures. As of December 31, 2025, unrecognized compensation cost of $3,201 related to RSUs will be recognized over a weighted-average period of 0.88 years.

For the years ended December 31, 2025, 2024 and 2023, the Company recognized nonvested stock amortization expense for the RSUs, which is included in General and administrative expenses as follows:

For the Years Ended December 31,

 

2025

2024

2023

General and administrative expenses

$

5,092

$

4,637

$

5,050

Performance-Based Restricted Stock Units

The Company has granted performance-based restricted stock units (“PRSUs”) under the 2015 Plan to certain employees of the Company, some of which are contingent upon the Company’s relative total shareholder return (“TSR”) and some of which are contingent upon the Company’s return on invested capital (”ROIC”) for a three-year performance period ending December 31, 2025 and December 31, 2026.

The TSR is calculated based on the Company’s total shareholder return compared to that of certain peer companies specified in the award agreements over the performance period and is calculated based on the change in the average daily closing stock price over a 20 trading-day period from the beginning to the end of the performance period, including reinvested dividends. The total quantity of PRSUs eligible to vest under these awards range from zero to 200% of the target based on actual relative TSR performance during the performance period. The grant date fair value of the TSR awards was estimated using a Monte Carlo simulation model. Compensation for these awards, which are subject to market conditions, is being amortized over the service period.

The grant date fair value of the ROIC awards was estimated using the closing share price of the Company’s stock on the date of grant. The total quantity of PRSUs eligible to vest under these awards range from zero to 200% of the target based on actual ROIC performance during the performance period. As such ROIC awards are subject to performance conditions and compensation cost is recognized over the service period based on the amounts of awards that the Company believes is probable that will vest, net of anticipated forfeitures. To the extent the Company’s estimate changes, the Company will recognize a cumulative catch up in subsequent reporting periods.

The table below summarizes the Company’s unvested PRSUs for the years ended December 31, 2025, 2024 and 2023:

For the years ended December 31, 

2025

2024

2023

Weighted

Weighted

Weighted

Number of

Average Grant

Number of

Average Grant

Number of

Average Grant

 

  ​ ​ ​

PRSUs

Date Price

PRSUs

Date Price

PRSUs

Date Price

 

Outstanding as of January 1,

 

178,903

$

20.45

79,838

$

18.97

$

Granted

 

145,792

17.01

99,065

21.64

79,838

18.97

Adjusted for performance results (a)

(5,193)

18.97

Vested

 

(74,645)

18.97

Forfeited

 

Outstanding as of December 31, 

 

244,857

$

18.88

178,903

$

20.45

79,838

$

18.97

(a)Represents the adjustment to previously granted PRSUs for performance results.

The total fair value of the PRSUs that vested during the year ended December 31, 2025 was $1,745. No PRSUs vested during the years ended December 31, 2024 and 2023.

The PRSUs, if earned, will ordinarily vest during the first quarter after the three-year performance period and the recipient will receive a share of common stock for each earned PRSU. If 100% of the target metric is achieved, the recipient will earn 100% of the target amount of the PRSUs originally granted. However, based on actual performance, the number of PRSUs earned will change based on the ranges described above. As of December 31, 2025, unrecognized compensation cost of $2,475 related to PRSUs will be recognized over a weighted-average period of 1.60 years.

Significant inputs used in the estimation of the fair value of these awards granted during the years ended December 31, 2025, 2024 and 2023 are as follows:

Significant Input

2025

2024

2023

Closing share price of our common stock

$14.85

$18.17

$16.20

Risk-free rate of return

4.24%

4.35%

3.84%

Expected volatility of our common stock

38.99%

48.34%

54.47%

Holding period discount

  ​ ​ ​

0%

0%

0%

 

Simulation term (in years)

  ​ ​ ​

2.86

2.86

2.71

 

Range of target

  ​ ​ ​

0% to 200%

0% to 200%

0% to 200%

 

For the years ended December 31, 2025, 2024 and 2023, the Company recognized nonvested stock amortization expense for the PRSUs, which is included in General and administrative expenses as follows:

For the years ended December 31, 

2025

2024

2023

General and administrative expenses

$

1,954

$

1,207

$

397

Historical Timeline

Fiscal YearFiled
2025Feb 18, 2026Showing above
2016Mar 28, 2017

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.